Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T17:07:26.132Z.
Calculation as of: 2026-10-06T17:07:26.132Z.
Quote observation: 2026-10-06T17:05:11.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a2c27257439ebc7e0324c407d6ec5b5d27bfaa5dcb56832ff3962ee146363265
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$107.44M
EV/Sales Ratio
N/A
TTM Avg
1.96x
3Y Avg
1.96x
5Y Avg
1.96x
Market Cap
$106.68M
EV/Sales Ratio
3.44x
TTM Avg
1.78x
3Y Avg
1.24x
5Y Avg
1.09x
Market Cap
$108.05M
EV/Sales Ratio
N/A
TTM Avg
103.10x
3Y Avg
102.99x
5Y Avg
102.99x
Market Cap
$108.20M
EV/Sales Ratio
N/A
TTM Avg
86.52x
3Y Avg
45.27x
5Y Avg
201.32x
Market Cap
$105.20M
EV/Sales Ratio
0.44x
TTM Avg
0.80x
3Y Avg
2.27x
5Y Avg
5.02x
Market Cap
$104.79M
EV/Sales Ratio
N/A
TTM Avg
501.64x
3Y Avg
356.48x
5Y Avg
292.72x
Market Cap
$104.68M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$110.12M
EV/Sales Ratio
2.09x
TTM Avg
3.15x
3Y Avg
1.92x
5Y Avg
2.95x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immunic, Inc. (IMUX) | $107.34M | N/A | N/A | N/A | N/A |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $107.44M | N/A | 1.96x | 1.96x | 1.96x |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $106.68M | 3.44x | 1.78x | 1.24x | 1.09x |
| Outlook Therapeutics, Inc. (OTLK)vs › | $108.05M | N/A | 103.10x | 102.99x | 102.99x |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $108.20M | N/A | 86.52x | 45.27x | 201.32x |
| Definitive Healthcare Corp. (DH)vs › | $105.20M | 0.44x | 0.80x | 2.27x | 5.02x |
| Anixa Biosciences, Inc. (ANIX)vs › | $104.79M | N/A | 501.64x | 356.48x | 292.72x |
| Polaryx Therapeutics, Inc. Common Stock (PLYX)vs › | $104.68M | N/A | N/A | N/A | N/A |
| Apyx Medical Corporation (APYX)vs › | $110.12M | 2.09x | 3.15x | 1.92x | 2.95x |
| BGM Group Ltd. (BGM)vs › | $111.14M | N/A | N/A | N/A | N/A |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
